Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Stopping GLP-1 drugs can quickly erase cardiovascular benefits – WashU Medicine (opens in a new tab)

medicine.washu.edu · 2026-03-18

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. One other point was not covered by the paper.

  • 3 supported
  • 1 overstated
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim overstates the study. Three of five check out. One claim the study doesn't address.

  • 3 supported
  • 1 overstated
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedAccording to a new study, people who stop GLP-1 drugs not only regain weight but also face increased risk of heart attack, stroke and death compared with staying on the medication.View evidenceHide evidence

Why this verdict

The cardiovascular portion is supported at the abstract level: among GLP-1RA initiators, discontinuation was associated with higher 3-year MACE risk versus continued use, and MACE was defined as myocardial infarction, stroke, or all-cause death. However, the supplied paper profile does not report weight regain as an outcome, so the claim’s 'not only regain weight' component is not supported by the paper profile. Also, the evidence is observational target-trial emulation, so the association should not be read as proven causation.

1

Study evidence

Compared with sulfonylurea initiators, GLP-1RA use for 0.5, 1.0, or 1.5 years followed by discontinuation showed incidence risk ratios close to 1.0 (no significant reduction in 3-year MACE).close to 1.0 (not statistically significant)

“Design Target trial emulation.”
2

Study evidence

Discontinuing GLP-1RA for 0.5 years (versus continued GLP-1RA use) was associated with a small but statistically significant increase in 3‑year MACE risk.IRR 1.04 (95% CI 1.01 to 1.08)

“Compared with continued use of GLP-1RA, discontinuing treatment for 0.5 years was associated with an increased risk of major adverse cardiovascular events...”
Claim 2 of 5Not coveredThe article attributes the study to Washington University School of Medicine in St. Louis and says the results appear in BMJ Medicine on March 18.View evidenceHide evidence

Why this verdict

The supplied abstract-level paper profile does not include author affiliation information tying the study to Washington University School of Medicine in St. Louis, nor does it provide the BMJ Medicine publication date of March 18. These bibliographic/news-release details cannot be verified from the provided profile.

Claim 3 of 5SupportedResearchers at Washington University School of Medicine in St. Louis followed more than 333,000 U.S. veterans with type 2 diabetes for three years and found that stopping or interrupting GLP-1 treatment for as little as six months was linked to a significant increase in major cardiovascular events.View evidenceHide evidence

As statedmore than 333,000 veterans; three years; as little as six months

Why this verdict

The abstract profile reports VA users with type 2 diabetes who initiated GLP-1RAs (n=132,551) or sulfonylureas (n=201,136), totaling more than 333,000 participants, with 3-year follow-up. Treatment status was reassigned every six months. Discontinuation for 0.5 years versus continued use had IRR 1.04 (95% CI 1.01 to 1.08), and 0.5-year interruption was reported qualitatively as associated with increased MACE risk. The story’s associational framing is consistent with the observational evidence.

1

Study evidence

Cohort sizes of incident users were reported as GLP-1RA n=132,551 and sulfonylurea n=201,136.

“Design Target trial emulation.”
2

Study evidence

Compared with sulfonylurea initiators, GLP-1RA use for 0.5, 1.0, or 1.5 years followed by discontinuation showed incidence risk ratios close to 1.0 (no significant reduction in 3-year MACE).close to 1.0 (not statistically significant)

“Design Target trial emulation.”
Claim 4 of 5SupportedThe article says the longer the treatment gap, the larger the risk increase, reaching a 22% increase for heart attack, stroke and death after two years off GLP-1s, largely erasing cardiovascular benefits gained during treatment.View evidenceHide evidence

As statedup to a 22% increase after two years off GLP-1s

Why this verdict

The profile supports a duration-response pattern: compared with continued GLP-1RA use, discontinuation for 0.5, 1, and 2 years was associated with progressively higher 3-year MACE risk, with the 2-year discontinuation estimate IRR 1.22 (95% CI 1.16 to 1.27), i.e., a 22% relative increase. MACE includes myocardial infarction, stroke, and all-cause death. The 'eroding/erasing benefit' framing is broadly consistent with the profile’s summary that discontinuation or interruption progressively eroded protection, though it remains observational evidence.

1

Study evidence

Compared with sulfonylurea initiators, GLP-1RA use for 0.5, 1.0, or 1.5 years followed by discontinuation showed incidence risk ratios close to 1.0 (no significant reduction in 3-year MACE).close to 1.0 (not statistically significant)

“Design Target trial emulation.”
2

Study evidence

Discontinuing GLP-1RA for 0.5 years (versus continued GLP-1RA use) was associated with a small but statistically significant increase in 3‑year MACE risk.IRR 1.04 (95% CI 1.01 to 1.08)

“Compared with continued use of GLP-1RA, discontinuing treatment for 0.5 years was associated with an increased risk of major adverse cardiovascular events...”
Claim 5 of 5SupportedThe story says the findings show continuous GLP-1 use provides the most cardiovascular benefit, while interruptions or discontinuation reduce that benefit and restarting the medication restores only some of it.View evidenceHide evidence

As stated18% reduction with continuous use; 12% reduction after interruption and resumption

Why this verdict

The profile reports that continuous GLP-1RA use for the full 3-year follow-up had the most pronounced reduction in MACE risk versus sulfonylureas (IRR 0.82, 95% CI 0.78 to 0.85), while discontinuation and interruption were associated with higher risk compared with continued use. Interruption analyses support the qualitative idea that resuming after a gap did not match the protection associated with uninterrupted use. The exact '12% reduction after interruption and resumption' figure is not visible in the supplied abstract-level profile, but the qualitative claim is supported.

1

Study evidence

Compared with sulfonylurea initiators, GLP-1RA use for 0.5, 1.0, or 1.5 years followed by discontinuation showed incidence risk ratios close to 1.0 (no significant reduction in 3-year MACE).close to 1.0 (not statistically significant)

“Design Target trial emulation.”
2

Study evidence

Discontinuing GLP-1RA for 0.5 years (versus continued GLP-1RA use) was associated with a small but statistically significant increase in 3‑year MACE risk.IRR 1.04 (95% CI 1.01 to 1.08)

“Compared with continued use of GLP-1RA, discontinuing treatment for 0.5 years was associated with an increased risk of major adverse cardiovascular events...”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Important limitation: the evidence is observational target-trial emulation, not a randomized trial proving that stopping GLP-1RAs causes MACE increases.

    The story uses mostly associational language, but the listed caveats do not explicitly note the observational nature or the residual-confounding concern. This is interpretation-changing because causal language such as treatment 'provides' benefit or stopping 'erodes' protection can outrun observational evidence.

    From Target trial emulation; Target trial emulation — dynamic post-initiation strategies

  • Non-cardiovascular outcomes: weight regain is not reported as an outcome in the supplied paper profile.

    The story’s lead claim mentions weight regain after stopping GLP-1 drugs, but the supplied abstract-level paper profile is focused on GLP-1RA treatment strategies and MACE; it does not provide evidence for weight regain.

7 things the story did carry across
  • Study design and data source: target trial emulation using US Veterans Affairs electronic healthcare data from the VA Corporate Data Warehouse, 2017-2023.
  • Population: incident users with type 2 diabetes, including 132,551 GLP-1RA initiators and 201,136 sulfonylurea initiators, followed for three years.
  • Comparator/reference: analyses compared GLP-1RA strategies with sulfonylurea initiators and also compared discontinuation/interruption with continued GLP-1RA use among GLP-1RA initiators.
  • Main outcome: 3-year cumulative incidence of major adverse cardiovascular events, defined as myocardial infarction, stroke, or all-cause death.
  • Main finding versus sulfonylureas: continuous GLP-1RA use for the full three years had the greatest reduction in MACE risk, IRR 0.82 (95% CI 0.78 to 0.85).
  • Within-GLP-1RA finding: discontinuation was associated with progressively higher MACE risk versus continued use, including IRR 1.04 for 0.5 years, IRR 1.14 for 1 year, and IRR 1.22 for 2 years.
  • Within-GLP-1RA finding: interruptions were associated with higher MACE risk versus continued use, with longer interruptions showing larger increases; the abstract profile does not provide a numeric IRR for the 0.5-year interruption contrast.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataEstimate the association between alternative GLP-1RA treatment strategies (duration of continued use, discontinuation, interruption) versus a sulfonylurea reference strategy on 3-year risk of major adverse cardiovascular events using a target trial emulation framework.Target trial emulationExpand

In plain English

Target-trial emulation using Veterans Affairs electronic healthcare data estimated associations between prespecified GLP-1RA treatment strategies (varying durations of continued use, discontinuation, or interruption) and 3-year risk of major adverse cardiovascular events (MACE: myocardial infarction, stroke, or all-cause death), using incident sulfonylurea initiators as the reference group. Continuous GLP-1RA use for longer durations was associated with progressively lower 3-year MACE risk versus sulfonylureas; shorter durations before discontinuation showed no clear benefit. Discontinuations or interruptions of GLP-1RA use were associated with progressively higher MACE risk compared with continued use.

Key findings

  • Compared with sulfonylurea initiators, GLP-1RA use for 0.5, 1.0, or 1.5 years followed by discontinuation showed incidence risk ratios close to 1.0 (no significant reduction in 3-year MACE).close to 1.0 (not statistically significant)
  • GLP-1RA use for 2.0 years then discontinuation was associated with reduced 3-year MACE risk versus sulfonylureas.IRR 0.93 (95% CI 0.88 to 0.98)
“Design Target trial emulation.”
2secondary dataCharacterise real-world patterns of GLP-1RA use scenarios in VA patients with type 2 diabetes, operationalised as dynamic treatment status updates every six months and prespecified continued-use/discontinuation/interruption strategies.Target trial emulation; incident-user cohort assembly; time-varying exposure operationalisationExpand

In plain English

Constructed an incident-user cohort of Veterans Affairs (VA) patients with type 2 diabetes using the VA Corporate Data Warehouse (2017–2023) to characterise real-world GLP-1RA use patterns. Incident users of GLP-1RAs (n=132,551) and sulfonylureas (n=201,136) were identified; treatment status in the GLP-1RA arm was reassigned every six months to implement 16 prespecified strategies varying continued use, discontinuation, and interruption over a three-year follow-up.

Key findings

  • Cohort sizes of incident users were reported as GLP-1RA n=132,551 and sulfonylurea n=201,136.
  • Exposure was operationalised by reassigning treatment status every six months in the GLP-1RA arm, generating 16 prespecified strategies that varied duration of continued use, discontinuation, or interruption.
“Design Target trial emulation.”
What this piece can’t prove
  • Abstract does not report methodological details for exposure ascertainment algorithms (e.g., refill windows, permissible gaps), covariate measurement/operationalisation, or handling of missing data.

1 further detail could not be confirmed from the summary.

3secondary dataEstimate, among GLP-1RA initiators, the comparative association of discontinuation and interruption (for varying durations) versus continued GLP-1RA use with 3-year risk of major adverse cardiovascular events.Target trial emulation — dynamic post-initiation strategiesExpand

In plain English

Target-trial emulation among 132,551 US Veterans Affairs GLP-1RA initiators evaluated how varying durations of discontinuation or interruption of GLP-1RA use (vs continued GLP-1RA use) related to 3-year cumulative risk of major adverse cardiovascular events (MACE: myocardial infarction, stroke, or all-cause death). Treatment status was reassigned every six months to define 16 prespecified post-initiation strategies; risk contrasts were reported as incidence risk ratios (IRRs) over three years.

Key findings

  • Discontinuing GLP-1RA for 0.5 years (versus continued GLP-1RA use) was associated with a small but statistically significant increase in 3‑year MACE risk.IRR 1.04 (95% CI 1.01 to 1.08)
  • Longer discontinuation durations were associated with progressively larger increases in 3‑year MACE risk compared with continued use.Discontinuation 1 year: IRR 1.14 (95% CI 1.09 to 1.18); discontinuation 2 years: IRR 1.22 (95% CI 1.16 to 1.27)
“Compared with continued use of GLP-1RA, discontinuing treatment for 0.5 years was associated with an increased risk of major adverse cardiovascular events...”
What this piece can’t prove
  • Abstract does not specify the analytic approach used to control confounding or the exact statistical models employed for the incidence risk ratio estimates.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 15 candidate papers

Candidate

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

Lancet (London, England) · 2026 · PubMed

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment

International Journal of Obesity · 2023 · Crossref

Tessa (opens in a new tab)Source (opens in a new tab)

And 9 more candidates considered.